{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:09:36Z","timestamp":1760144976797,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background\/Objectives: Relapsed B-cell acute lymphoblastic leukemia (B-ALL) remains an unresolved matter of concern regarding adverse outcomes. This case study aimed to evaluate the effectiveness of blinatumomab, with or without door lymphocyte infusion (DLI), in treating measurable residual disease (MRD)-positive B-ALL. Methods: All patients who received blinatumomab salvage therapy were included in this study. Eleven patients were included in the study. All patients were evaluated for MRD-negativity. Results: Before starting blinatumomab therapy, seven patients tested positive for MRD, three tested negative, and one had refractory disease. Hematopoietic cell transplantation (HCT) was reserved for five patients with persistent MRD. Six patients became MRD-negative and subsequent HCT was not performed. Only two patients relapsed; one patient died of relapse, and the other one received carfilzomib-based therapy and was MRD-negative thereafter. Nine patients were MRD-negative at a median follow-up of 28 months (15\u201352 months). Two of three MRD-positive post-transplant patients remained in complete molecular remission after preemptive DLI at the last follow-up date. In the first salvage, blinatumomab may achieve complete remission and bridging to HCT in pediatric patients with end-of-induction MRD-positive B-cell precursor ALL. Conclusions: The decision on how to treat post-transplant relapse continues to affect survival outcomes. Blinatumomab combined with DLI may extend the armamentarium of release options for high-risk pediatric patients. This approach is encouraging for high-risk ALL patients who are MRD-positive post-transplantation.<\/jats:p>","DOI":"10.3390\/hematolrep16020035","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:29:47Z","timestamp":1717417787000},"page":"347-353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blinatumomab in Children with MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 11 Cases"],"prefix":"10.3390","volume":"16","author":[{"given":"Yi-Lun","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology, Chang Gung Memorial Hospital, Taoyuan 33315, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Yen","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology, Chang Gung Memorial Hospital, Taoyuan 33315, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chuan","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Nursing, Chang Gung Memorial Hospital, Taoyuan 33315, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Ho","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nursing, Chang Gung Memorial Hospital, Taoyuan 33315, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Nursing, Chang Gung Memorial Hospital, Taoyuan 33315, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chi","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Nursing, Chang Gung Memorial Hospital, Taoyuan 33315, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chieh","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruei-Shan","family":"Hu","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-2735","authenticated-orcid":false,"given":"Shih-Hsiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology, Chang Gung Memorial Hospital, Taoyuan 33315, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5407-1555","authenticated-orcid":false,"given":"Tang-Her","family":"Jaing","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology, Chang Gung Memorial Hospital, Taoyuan 33315, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Cheng","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1188582","DOI":"10.3389\/fimmu.2023.1188582","article-title":"Editorial: The immune escape mechanism and novel immunotherapeutic strategies of leukemia","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5045\/br.2022.2021163","article-title":"Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk","volume":"57","author":"Wo","year":"2022","journal-title":"Blood Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of Postreinduction Therapy Consolidation with Blinatumomab vs. Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults with First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children with High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Queudeville, M., and Ebinger, M. (2021). Blinatumomab in Pediatric Acute Lymphoblastic Leukemia\u2014From Salvage to First Line Therapy (A Systematic Review). J. Clin. Med., 10.","DOI":"10.3390\/jcm10122544"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease","volume":"25","author":"Jen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.leukres.2012.09.012","article-title":"Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure","volume":"37","author":"Shih","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jfma.2016.12.002","article-title":"Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes","volume":"116","author":"Huang","year":"2017","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/cyto.b.21101","article-title":"Detection of minimal residual disease in pediatric acute lymphoblastic leukemia","volume":"84","author":"Gaipa","year":"2013","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"807002","DOI":"10.3389\/fped.2021.807002","article-title":"What Is the Role of HSCT in Philadelphia-Chromosome-Positive and Philadelphia-Chromosome-Like ALL in the Tyrosine Kinase Inhibitor Era?","volume":"9","author":"Vettenranta","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kaczmarska, A., \u015aliwa, P., Zawitkowska, J., and Lejman, M. (2021). Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126411"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"20406207221099468","DOI":"10.1177\/20406207221099468","article-title":"Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: A therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports)","volume":"13","author":"Poyer","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/bloodadvances.2021005579","article-title":"Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis","volume":"6","author":"Locatelli","year":"2022","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-022-00766-7","article-title":"Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: Results from the NEUF study","volume":"13","author":"Boissel","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E113","DOI":"10.1002\/ajh.26880","article-title":"Timing of intrathecal chemotherapy and blinatumomab impacts neurotoxicity in acute lymphoblastic leukemia","volume":"98","author":"Lee","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/bcj.2014.64","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41409-022-01846-9","article-title":"Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: A study of the SFGM-TC","volume":"58","author":"Chauvet","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"795833","DOI":"10.3389\/fped.2021.795833","article-title":"Bispecific antibodies and other non-CAR targeted therapies and HSCT: Decreased toxicity for better transplant outcome in paediatric ALL?","volume":"9","author":"Algeri","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/bmt.2016.104","article-title":"Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant","volume":"51","author":"Ueda","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1177\/1060028020988411","article-title":"A systematic review of blinatumomab in the treatment of acute lymphoblastic leukemia: Engaging an old problem with new solutions","volume":"55","author":"Halford","year":"2021","journal-title":"Ann. Pharmacother."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/2\/35\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:52:46Z","timestamp":1760107966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/2\/35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["hematolrep16020035"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep16020035","relation":{},"ISSN":["2038-8330"],"issn-type":[{"type":"electronic","value":"2038-8330"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}